Pliant Therapeutics announced that the latest data from the Phase 1 clinical trial of its investigational drug Pln-101095 for patients with immune checkpoint inhibitor (ICI)-refractory solid tumors will be presented in a special report at the 2026 American Association for Cancer Research (AACR) Annual Meeting.

老虎证券2026/04/18 17:43

Show original

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Federal Reserve Beige Book: Economy Expanding Moderately, Data Center Demand Becomes Main Driver

The latest Beige Book survey released by the Federal Reserve shows that U.S. economic activity experienced moderate growth over the past two months, with particularly strong demand from data centers emerging as a major driving force for the economy.

智通财经•2026/09/02 23:21

Palantir CEO Reportedly Says France's Digital Sovereignty Drive 'Backfiring'

MT newswire•2026/09/02 23:14

2-Yr Benchmark Govt Yields - U.S. vs Other Nations

Dow Jones•2026/09/02 23:10

2-Yr Benchmark Govt Yields - Germany vs Other Nations

Dow Jones•2026/09/02 23:10